Last Updated: September 29, 2026

Details for New Drug Application (NDA): 204516

✉ Email this page to a colleague

NDA 204516 describes BRISDELLE, which is a drug marketed by Legacy and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the BRISDELLE profile page.

The generic ingredient in BRISDELLE is paroxetine mesylate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

Summary for 204516

Tradename:	BRISDELLE
Applicant:	Legacy
Ingredient:	paroxetine mesylate
Patents:	3

Pharmacology for NDA: 204516

Mechanism of Action	Serotonin Uptake Inhibitors

Suppliers and Packaging for NDA: 204516

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516	NDA AUTHORIZED GENERIC	Padagis US LLC	0574-0279	0574-0279-30	30 CAPSULE in 1 BOTTLE (0574-0279-30)
BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516	NDA	Legacy Pharma USA, Inc.	83107-027	83107-027-30	30 CAPSULE in 1 BLISTER PACK (83107-027-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 7.5MG BASE
Approval Date:	Jun 28, 2013	TE:	AB	RLD:	Yes
Patent:	8,658,663	Patent Expiration:	Apr 6, 2029	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Patent:	8,946,251	Patent Expiration:	Aug 4, 2026	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Patent:	9,393,237	Patent Expiration:	Aug 4, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Expired US Patents for NDA 204516

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Legacy	BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516-001	Jun 28, 2013	5,874,447	⤷ Start Trial
Legacy	BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516-001	Jun 28, 2013	9,393,237	⤷ Start Trial
Legacy	BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516-001	Jun 28, 2013	7,598,271	⤷ Start Trial
Legacy	BRISDELLE	paroxetine mesylate	CAPSULE;ORAL	204516-001	Jun 28, 2013	8,946,251	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.